Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee

 
• By Derrick Gingery

Some Endocrinologic and Metabolic Drugs Advisory Committee members said a REMS is sufficient, but others worried that proposed risk management plans were not proven effective.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers